News coverage about Kala Pharmaceuticals (NASDAQ:KALA) has been trending somewhat positive on Wednesday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Kala Pharmaceuticals earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.5791180112068 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
- Kala Pharmaceuticals Inc (KALA) Expected to Post Earnings of -$0.44 Per Share (americanbankingnews.com)
- Kala Pharmaceuticals Appoints Eric Trachtenberg as General Counsel and Corporate Secretary (finance.yahoo.com)
- Short Interest in Kala Pharmaceuticals Inc (KALA) Drops By 21.7% (americanbankingnews.com)
- Kala Pharmaceuticals 2017 Q4 – Results – Earnings Call Slides (seekingalpha.com)
NASDAQ KALA opened at $15.74 on Wednesday. Kala Pharmaceuticals has a twelve month low of $11.81 and a twelve month high of $26.75. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.00 and a current ratio of 11.00. The company has a market cap of $388.17 and a price-to-earnings ratio of -2.70.
Several research analysts have issued reports on KALA shares. Wells Fargo restated a “buy” rating on shares of Kala Pharmaceuticals in a research report on Friday, January 5th. Wedbush restated an “outperform” rating and issued a $46.00 price target on shares of Kala Pharmaceuticals in a research report on Friday, December 22nd. Finally, BidaskClub upgraded shares of Kala Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, December 29th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. Kala Pharmaceuticals has a consensus rating of “Buy” and an average target price of $35.80.
In other news, major shareholder Orbimed Advisors Llc acquired 170,338 shares of the stock in a transaction on Wednesday, January 10th. The shares were purchased at an average cost of $12.83 per share, for a total transaction of $2,185,436.54. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last quarter, insiders have acquired 1,108,150 shares of company stock worth $15,772,394.
ILLEGAL ACTIVITY NOTICE: “Kala Pharmaceuticals (NASDAQ:KALA) Earns Daily News Sentiment Score of 0.18” was published by BBNS and is the sole property of of BBNS. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://baseballnewssource.com/2018/04/04/kala-pharmaceuticals-kala-getting-somewhat-positive-press-coverage-accern-reports/2019149.html.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.